Retatrutide Dosage Protocol

The phase 2 retatrutide obesity trial (n = 338) reported a mean body weight reduction of 24.2% at 48 weeks on the 12 mg weekly dose, the largest magnitude weight-loss effect reported for any investigational obesity agent in a randomized controlled trial to date [1]. Retatrutide is a 39-amino-acid synthetic peptide engineered as a triple agonist at the GLP-1, GIP, and glucagon receptors, administered once weekly by subcutaneous injection [2].

Reported protocols in published phase 2 data span 1 mg to 12 mg weekly with a graduated 4- to 12-week titration schedule; no protocol has been evaluated in phase 3 at the time of writing, and the molecule is not approved by any regulatory authority.

How Retatrutide Works: Mechanism of Action

In short: retatrutide hits three metabolism receptors at once — the two tirzepatide hits, plus glucagon — and the glucagon arm is what pushes weight loss past anything we've seen from pure incretin drugs.

Retatrutide (Eli Lilly compound code LY3437943) is a novel unimolecular triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR) [2]. The molecule is built on a modified GIP/glucagon backbone with specific substitutions that confer balanced agonist activity at all three receptors and a fatty diacid linker that supports albumin binding for extended half-life.

Receptor potency data from in vitro assays indicate that retatrutide has substantial activity at all three receptors, with GLP-1R activity somewhat lower than semaglutide and glucagon receptor activity intentionally tuned to provide additive metabolic effects without inducing hyperglycemia [2]. The glucagon receptor component is hypothesized to contribute to the larger weight-loss effect observed relative to pure GLP-1 or dual GIP/GLP-1 agonists by increasing hepatic fat oxidation, raising basal metabolic rate, and enhancing lipolysis [2,3].

The phase 2 obesity trial enrolled 338 adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity, randomized to retatrutide 1, 4, 8, or 12 mg weekly or placebo for 48 weeks [1]. Weight loss was dose-responsive: 8.7% at 1 mg, 17.1% at 4 mg, 22.8% at 8 mg, and 24.2% at 12 mg, versus 2.1% for placebo. The 4 mg dose approximated semaglutide 2.4 mg outcomes, and 8 and 12 mg doses exceeded any previously reported incretin-based therapy.

A parallel phase 2 trial in type 2 diabetes (n = 281) reported HbA1c reductions up to 2.16% and weight reductions up to 16.9% at 48 weeks across dose arms 0.5 mg to 12 mg [4]. A phase 2 trial in metabolic dysfunction-associated steatohepatitis (MASH) reported substantial reductions in liver fat content and resolution of steatohepatitis at weekly doses of 1 to 12 mg [5].

Terminal half-life after a single subcutaneous dose is approximately 6 days [2], supporting once-weekly administration with steady-state achieved after 4 to 5 weeks of fixed dosing. Phase 3 trials (TRIUMPH program) are in progress but had not reported primary outcomes as of this writing.

Retatrutide Dose Ranges in the Peer-Reviewed Literature

In short: published phase 2 protocols ran retatrutide at 1 to 12 mg weekly, with the highest weight-loss response at 12 mg after a slow 20-week titration.

The phase 2 obesity trial titration schedule ascended from 2 mg (starting dose) in weekly or bi-weekly increments to target dose [1]. For the 12 mg target arm: 2 mg × 4 weeks, 4 mg × 4 weeks, 6 mg × 4 weeks, 8 mg × 4 weeks, 10 mg × 4 weeks, 12 mg thereafter, for a total titration period of approximately 20 weeks. The 4 mg arm reached target in approximately 8 weeks; the 8 mg arm in approximately 16 weeks.

The type 2 diabetes trial used a faster titration schedule (2 mg × 2 weeks, 4 mg × 2 weeks, escalating every 2 weeks) at lower target doses, reaching 4 mg target in 4 weeks and 12 mg target in 12 weeks [4]. The faster titration was associated with numerically higher GI adverse-event rates relative to the slower obesity-trial schedule.

No "maintenance dose" standard has been established because phase 3 has not reported. Published phase 2 data show a clear dose-response up to 12 mg with no evidence of plateau, but whether 12 mg is the optimal phase 3 target is not yet determined. Some phase 3 arms include a 16 mg cohort not present in phase 2.

Retatrutide is not available as an approved product. It is available only through enrollment in a registered clinical trial, or through gray-market "research chemical" channels that have not been evaluated for identity or purity in any systematic peer-reviewed study.

Retatrutide Reconstitution: Math and Worked Examples

In short: target doses above 8 mg typically won't fit in a single standard 100-unit insulin syringe unless you reconstitute to higher concentrations. Check the math before you load.

As an investigational compound, retatrutide has no standardized pre-filled pen; research-chemical vendors supply lyophilized powder in varied vial sizes. Most commonly distributed vial sizes reported in the gray market are 5 mg, 10 mg, and 15 mg.

Formula: Concentration (mg/mL) = Vial peptide (mg) ÷ BAC water added (mL)

Worked example — 10 mg vial with 2 mL BAC water:

• Final concentration: 10 mg ÷ 2 mL = 5 mg/mL
• For a 2 mg initiation dose: 2 mg ÷ 5 mg/mL = 0.4 mL = 40 units on a U-100 insulin syringe
• For a 4 mg dose: 0.8 mL = 80 units
• For an 8 mg dose: 1.6 mL = 160 units — exceeds single U-100 syringe; requires split injection or higher vial concentration
• For a 12 mg dose: 2.4 mL — exceeds the reconstituted volume

15 mg vial with 1.5 mL BAC water:

• Final concentration: 10 mg/mL
• 2 mg = 0.2 mL = 20 units
• 4 mg = 0.4 mL = 40 units
• 8 mg = 0.8 mL = 80 units
• 12 mg = 1.2 mL = 120 units (still exceeds standard U-100 syringe)

5 mg vial with 1 mL BAC water (low-concentration option):

• Final concentration: 5 mg/mL
• 2 mg = 0.4 mL = 40 units

At target doses above 8 mg, higher vial concentrations become necessary to keep injection volumes within a standard 100-unit U-100 insulin syringe. Stability data for reconstituted retatrutide in BAC water is limited and drawn primarily from internal manufacturer characterization; 28 days under refrigeration is a conservative assumption by analogy to other incretin peptides.

How Retatrutide Is Administered

In short: subcutaneous, weekly, fixed day. Trial protocols allowed a 3-day miss-dose window; the slower obesity titration schedule tolerated GI side effects better than the aggressive diabetes titration.

Phase 2 trials administered retatrutide once weekly by subcutaneous injection. Injection sites described in the trial protocols were the abdomen, thigh, and upper arm, rotated per standard research practice [1,4]. A 29–31 gauge, 4–8 mm needle is appropriate for subcutaneous injection at typical phase 2 injection volumes.

A fixed day-of-week was maintained across the trial duration for each participant to minimize steady-state variability [1]. No meal-timing requirement was specified; dosing was not food-dependent.

Titration between dose steps followed a minimum 4-week interval in the obesity trial and a 2-week interval in the more aggressively titrated diabetes trial [1,4]. The slower obesity schedule is associated with lower GI adverse-event rates and is more likely to be recapitulated in phase 3 obesity studies.

Missed-dose rules in the phase 2 protocols permitted administration within 3 days of the scheduled date; beyond that window, the dose was skipped and resumed on the next scheduled day. Given the 6-day half-life, extended delays approach the threshold where reinitiation at the previous dose may exceed tolerance.

Phase 2 trials excluded patients on concurrent GLP-1 receptor agonists, SGLT-2 inhibitors, and certain other glucose-lowering agents. Concurrent use with sulfonylureas and insulin (in the type 2 diabetes trial) required anticipatory dose reduction to prevent hypoglycemia [4].

Retatrutide Cycle Structure and Protocol Duration

In short: published phase 2 data covers 48 weeks; nothing is known about planned cycling, and discontinuation dynamics have not been published.

Phase 2 treatment durations were 48 weeks for obesity and MASH and 36 weeks for type 2 diabetes [1,4,5]. There is no peer-reviewed published data on retatrutide dosing beyond 48 weeks, and no published data on planned discontinuation, washout, or cycling.

Because retatrutide sits in the same mechanistic family as semaglutide and tirzepatide, similar weight-regain dynamics on discontinuation are plausible but not established. No tolerance or tachyphylaxis has been reported within the 48-week phase 2 window.

Dose reductions for intolerance were permitted in the phase 2 protocols, with participants who could not tolerate a given titration step allowed to remain at the prior dose for additional weeks or drop one step. Titration pauses longer than 4 weeks at a given step were uncommon in the trial population.

Post-discontinuation washout approximates five half-lives (approximately 30 days). Phase 3 trials will generate long-term durability and discontinuation data; these were not available at the time of writing.

Retatrutide Side Effects and Safety Profile

In short: GI side effects at 12 mg are heavier than semaglutide or tirzepatide (nausea ~41%); resting heart rate rises 6-8 bpm; hepatic safety in MASH was favorable but long-term safety is unresolved.

The phase 2 adverse-event profile is dominated by gastrointestinal side effects, consistent with the GLP-1 class and amplified somewhat by the glucagon receptor component. In the 48-week obesity trial at 12 mg, nausea was reported by 41% (vs. 16% placebo), diarrhea by 30%, vomiting by 20%, and constipation by 16% [1]. GI events were most frequent during titration and declined thereafter.

Modest, dose-dependent increases in resting heart rate were observed in the phase 2 program (approximately 6–8 bpm at 12 mg) and are attributed to the glucagon receptor component [1,4]. Transient, mild elevations in alanine aminotransferase were reported in a subset of participants in the MASH trial, though overall hepatic safety was favorable and steatohepatitis resolution was observed [5].

Hypoglycemia was uncommon in non-diabetic obesity participants and was largely limited to those on concurrent sulfonylureas in the diabetes trial [4]. Injection-site reactions occurred in a small minority and were generally mild.

Retatrutide has not been evaluated in pregnant or lactating women, pediatric populations, or patients with severe renal or hepatic impairment. Personal or family history of medullary thyroid carcinoma and MEN 2 were exclusion criteria in phase 2 by analogy to other incretin-based therapies pending thyroid-safety data from long-term studies [1]. No regulatory boxed warning exists because the molecule is not approved.

Drug interactions are expected to be minimal given retatrutide's peptide nature, but delayed gastric emptying may alter oral drug absorption in a class-typical manner. The rate of hormonal contraceptive interaction has not been specifically studied.

Retatrutide Vendor Ratings: Who Publishes Lab Data at ≥99% Purity?

Which retatrutide vendors publish lab data ≥99% purity?

Retatrutide is not available as an approved medicine. It is sold in the research-chemical channel by vendors of variable quality. TriedRx aggregates publicly available third-party lab reports (HPLC identity, mass spectrometry, endotoxin), transparency disclosures, reputation signals, and operational data on retatrutide vendors — then grades them on a transparent rubric. We do not run our own chromatography. Because retatrutide is a structurally complex triple agonist, synthesis failure modes (truncated sequences, deamidation, incomplete chain folding) show up more often in the published lab reports we've reviewed than for simpler peptides. No vendor pays for inclusion; we accept no sponsored placement.

See all retatrutide vendors we rate → /brands?peptide=retatrutide

Related: Retatrutide Research Profile and Vendor Rankings

For full research background on retatrutide, including mechanistic details on triple receptor agonism, phase 2 trial summaries, and the aggregated third-party lab data we compile on vendor quality, see the TriedRx retatrutide profile. Related content includes the dosing protocols for tirzepatide, semaglutide, survodutide, and mazdutide.

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315.

1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PMID: 36309206.

1. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PMID: 37356205.

1. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. PMID: 36354040.

1. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PMID: 38587896.

1. Eli Lilly and Company. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1). ClinicalTrials.gov identifier NCT05882045.

1. Knerr PJ, Mowery SA, Finan B, et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metab. 2022;63:101533. PMID: 35863638.